| ²é¿´: 291 | »Ø¸´: 9 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||
[½»Á÷]
¸÷λ¸ßÊÖÇë½ø
|
|||
The active substance manufacturer's restricted ("closed" part of the EDMF should follow thestructure of Module 3.2.S of the CTD. A separate Quality Overall Summary for the information included in the active substance manufacturer's restricted ("closed" part shouldalso be provided, as part of the EDMF. ÕâÒ»¶ÎÊDz»ÊÇ˵Ã÷CTDÖÐÖÁÉÙÊÇÅ·ÖÞµÄÖÆ¼ÁÉ걨,³ýÁËÊÚȨÐÅÒÔÍâ,»¹ÊÇÐèÒªÔÁÏÒ©DMFµÄ¹«¿ª²¿·ÖÎļþºÍ·Ç¹«¿ª²¿·ÖÎļþÁ˰¡,²»ÊÇ˵²»Ó÷ǹ«¿ªµÄ²¿·ÖÂð, |
» ²ÂÄãϲ»¶
¿¼Ñе÷¼Á£º¹ú¼Òµ°°×ÖÊ¿ÆÑ§ÖÐÐÄ£¨¹ú¼ÒÖØµãʵÑéÊÒ£©ºÍ°²»ÕÒ½¿Æ´óѧ»ù´¡Ò½Ñ§ÔºÁªÅà
ÒѾÓÐ4È˻ظ´
»ªÄÏÀí¹¤´óѧ »ù´¡Ò½Ñ§Ñ§Ë¶ºÍÁÙ´²Ò½Ñ§Ñ§Ë¶µ÷¼Á
ÒѾÓÐ11È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ260È˻ظ´
¹ãÎ÷Ò½¿Æ´óѧ»ù´¡Ò½Ñ§ÔºÕÐÊÕ»ù´¡Ò½Ñ§¡¢Ò©Ñ§¡¢ÉúÎï¼ìÑéÏà¹Ø×¨ÒµµÄÑо¿Éú
ÒѾÓÐ1È˻ظ´
±±¾©ÐºÍҽѧԺ½ÜÇà¿ÎÌâ×éÕÐÆ¸¿ÆÑÐÖúÀí
ÒѾÓÐ0È˻ظ´
±±¾©ÐºÍҽѧԺ½ÜÇà¿ÎÌâ×éÕÐÆ¸¿ÆÑÐÖúÀí
ÒѾÓÐ0È˻ظ´
ÇóÖúÖйúÒ©µä1995Äê°æ¡¢¶þ²¿
ÒѾÓÐ0È˻ظ´
±±¾©ÐºÍҽѧԺ½ÜÇà¿ÎÌâ×éÕÐÆ¸¿ÆÑÐÖúÀí
ÒѾÓÐ0È˻ظ´
ÇóÖúhttps://www.pnas.org/doi/10.1073/pnas.2535777123 È«ÎÄ
ÒѾÓÐ0È˻ظ´
6Â¥2007-03-05 14:27:55
2Â¥2007-03-04 19:00:57
3Â¥2007-03-04 19:01:12
4Â¥2007-03-05 09:21:36









part of the EDMF should follow the
»Ø¸´´ËÂ¥
ͶƱ: